08-10 KNC Laboratories Co., Ltd.'s Equity Buyback announced on May 13, 2022, has closed with 120,000 shares, representing 1.55% for ¥152.4 million. CI
08-10 Tranche Update on KNC Laboratories Co., Ltd.'s Equity Buyback Plan announced on August 7, 2026. CI
08-07 KNC Laboratories Co., Ltd. authorizes a Buyback Plan. CI
08-07 KNC Laboratories Co., Ltd. announces an Equity Buyback for 120,000 shares, representing 1.55% for ¥152.4 million. CI
02-03 Immunorock Co., Ltd. announced that it has received ¥383.3 million in funding from Osaka University Venture Capital Co., Ltd., Kobe University Capital Co., Ltd., SBI Daigaku Hatsu Venture Ikusei Shien Co., Ltd., Ai Fusion Capital Group Corp., KNC Laboratories Co., Ltd., Kobe Shinkin Bank CI
24-03-13 KNC Laboratories Co., Ltd. acquired an unknown stake in NapaJen Pharma, Inc. from INCJ, Ltd. CI
22-05-15 Tranche Update on KNC Laboratories Co., Ltd.'s Equity Buyback Plan announced on May 13, 2022. CI
22-05-15 KNC Laboratories Co., Ltd.'s Equity Buyback announced on May 13, 2022, has closed with 100,000 shares, representing 1.29% for ¥111.5 million. CI
22-05-13 KNC Laboratories Co., Ltd. announces an Equity Buyback for 100,000 shares, representing 1.29% for ¥111.5 million. CI
22-05-12 KNC Laboratories Co., Ltd. authorizes a Buyback Plan. CI
18-09-09 Certain Common Shares of KNC Laboratories Co., Ltd. are subject to a Lock-Up Agreement Ending on 10-SEP-2018. CI
18-03-14 KNC Laboratories Co., Ltd. has completed an IPO in the amount of ¥5.30712 billion. CI
18-02-09 KNC Laboratories Co., Ltd. has filed an IPO. CI
1 day-0.86%
1 week-1.24%
Current month+3.25%
1 month+2.91%
3 months+2.67%
6 months-0.78%
Current year+13.08%
1 week 1,255
Extreme 1255
1,290
1 month 1,190
Extreme 1190
1,298
Current year 1,113
Extreme 1113
1,418
1 year 1,060
Extreme 1060
1,418
3 years 957
Extreme 957
1,630
5 years 957
Extreme 957
2,167
10 years 954
Extreme 954
4,830
Manager TitleAgeSince
President 58 2023-05-31
Corporate Officer/Principal 55 2006-04-30
Human Resources Officer 64 2023-05-31
Director TitleAgeSince
Director/Board Member 79 2017-02-28
Director/Board Member 58 2018-05-31
Director/Board Member 70 2022-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.86%-1.24%+10.33%-18.47% 62.07M
-0.10%+1.52%+14.78%+37.14% 234B
-0.11%+0.37%+10.24%+31.57% 124B
-1.60%-4.88%-9.49%+35.91% 78.68B
+7.23%-0.47%+655.92%+412.86% 72.76B
+0.03%+1.50%+20.74%+11.24% 68.39B
-0.88%+4.10%-21.88%-38.38% 38.11B
+0.18%+5.99%+14.61%-19.80% 33.01B
+4.41%+7.51%+12.47%-1.89% 25.22B
+1.04%+12.34%+34.48%-29.06% 24.54B
Average +0.93%+3.98%+74.22%+42.11% 69.9B
Weighted average by Cap. +0.68%+2.42%+77.17%+62.05%

Financials

2019 *2020 *
Net sales 6.3B 39.82M 35.73M 33.03M 29.91M 55.89M 3.79B 56.56M 395M 157M 1.98B 149M 146M -
Net income 830M 5.25M 4.71M 4.35M 3.94M 7.36M 500M 7.45M 52.03M 20.72M 261M 19.69M 19.27M -
Net Debt - -
Logo KNC Laboratories Co., Ltd.
KNC Laboratories Co., Ltd. researches, develops and produces solution business of organic chemicals. The company supplies necessary samples and products for research, development and production activities for product development, manufacture and sale, and also examines the manufacturing method. Organic chemical products are chemical products and intermediates used in the field of medicine and information electronics. Products include display materials, chemicals for semiconductor manufacturing, herbicides, fungicides, drug substances and intermediates, among others.
Employees
219
Date Price Change Volume
26-10-28 JP¥1,271.00 -0.86% 700
26-10-28 JP¥1,282.00 +0.47% 6,300
26-10-27 JP¥1,276.00 +0.47% 100
26-10-26 JP¥1,270.00 -0.31% 9,300
26-10-23 JP¥1,274.00 -1.01% 5,700
  1. Stock Market
  2. Stocks
  3. 6568 Stock